NCD

NCD assesses, advises on impact of Supreme Court Cummings decision

Retrieved on: 
Thursday, January 19, 2023
Rehabilitation, NCD, National Council, Congress, Cummings, National Council on Disability, Supreme, An act to repeal the Patient Protection and Affordable Care Act, Section 504 of the Rehabilitation Act, Rehabilitation Act of 1973, Policy, Civil Rights Act of 1991, Civil and political rights, Disability, Constitutional challenges to the Affordable Care Act, Supreme court, Care Act 2014, Distress, Health insurance

Cummings v. Premier Rehab Keller PLLC: Implications and Avenues for Reform examines the U.S. Supreme Court decision of April 28, 2022.

Key Points: 
  • Cummings v. Premier Rehab Keller PLLC: Implications and Avenues for Reform examines the U.S. Supreme Court decision of April 28, 2022.
  • "With the Cummings decision, the U.S. Supreme Court has rolled back the clock 50 years to an era when it was permissible to subject the ‘handicapped’ to separate and unequal treatment without repercussion," said NCD Chairman Andrés Gallegos.
  • The policy brief concludes by recommending a legislative fix to the Supreme Court decision.
  • NCD is an independent, nonpartisan federal agency that advises the President, Congress and other federal agencies on disability policy.

DecisionHealth partners with innoviHealth to offer an HCC calculator add-on to SelectCoder, the premier online coding resource

Retrieved on: 
Wednesday, January 18, 2023
NCD, Risk, CCI, LCD, CMS, Partnership, AMA, Policy, Hierarchy, HCC, Programmer, Credit, Medical device

BRENTWOOD, Tenn., Jan. 18, 2023 /PRNewswire-PRWeb/ -- DecisionHealth, an HCPro brand, is proud to announce the launch of a new optional supplement to SelectCoder: a Hierarchical Condition Category (HCC) calculator. The HCC calculator is used to calculate patient risk scores based on HCCs. Through a partnership with innoviHealth, the privately held, Utah-based parent company of Find-A-Code, HCC Coder, ChiroCode, QPro, Codapedia, and the Healthcare Administration Alliance, DecisionHealth can provide SelectCoder subscribers with the new HCC calculator functionality, giving them the ability to quickly find risk scores based on diagnoses and demographic factors.

Key Points: 
  • DecisionHealth, an HCPro brand, is proud to announce the launch of a new add-on option for SelectCoder: a Hierarchical Condition Category (HCC) calculator.
  • The HCC calculator is used to calculate patient risk scores based on HCCs.
  • BRENTWOOD, Tenn., Jan. 18, 2023 /PRNewswire-PRWeb/ -- DecisionHealth, an HCPro brand, is proud to announce the launch of a new optional supplement to SelectCoder: a Hierarchical Condition Category (HCC) calculator.
  • Using the HCC calculator, subscribers can easily calculate risk scores for an individual patient or process cases in bulk.

ALZHEIMER'S ASSOCIATION STATEMENT: ALZHEIMER'S ASSOCIATION WELCOMES U.S. FDA APPROVAL OF LECANEMAB

Retrieved on: 
Friday, January 6, 2023
Alzheimer's Association, Dementia, Amyloid, Doctor of Public Health, National coverage determination, Plasma protein binding, Ageing, Legislation, Health, NCD, Food, Drug discovery, Research, Network, Center for Medicare and Medicaid Innovation, Brain, Helpline, Multimedia, Disease, Communes of Burundi, Science, Patient, Family, Centers for Medicare & Medicaid Services, Letter, Treatment, Insurance, FDA, Antibody, Food and Drug Administration, Congress, MCI, Diagnosis, CMS, Medicare, Health insurance, Pharmaceutical industry, Medical imaging, Alzheimer's disease

CHICAGO, Jan. 6, 2023 /PRNewswire/ -- The Alzheimer's Association enthusiastically welcomes today's U.S. Food and Drug Administration (FDA) action to grant the accelerated approval of Leqembi™ (lecanemab) (Eisai/Biogen) for the treatment of patients in mild cognitive impairment (MCI) or mild dementia stage of Alzheimer's disease and with confirmation of amyloid beta. While this is a milestone achievement for people eligible for the treatment, their families and the research community, without Centers for Medicare & Medicaid Services (CMS) and insurance coverage of this treatment and others in its class, access for those who could benefit from the newly-approved treatment will only be available to those who can pay out-of-pocket.

Key Points: 
  • "What the FDA did today in granting accelerated approval to Leqembi was the right decision.
  • "The FDA carefully reviewed the evidence for Leqembi before granting approval.
  • CMS has never done this before for any drug, and it is clearly harmful and unfair to those with Alzheimer's.
  • Leqembi was approved through the FDA's accelerated approval pathway, which grants earlier approval to drugs that treat serious conditions and fill an unmet medical need.

Alzheimer's Association Calls on CMS to Reverse Its Decision to Severely Limit Access to FDA-Approved Alzheimer's Disease Treatments

Retrieved on: 
Tuesday, December 20, 2022
Dementia, Antibody, CMS, Food, NCD, Brain, Alzheimer's Association, Disease, Helpline, Medicare, FDA, Clarity, Amyloid, Multimedia, MCI, Centers for Medicare & Medicaid Services, Doctor of Public Health, Food and Drug Administration, HIV disease progression rates, CED, Letter, Ageing, Policy, Pharmaceutical industry, Medical imaging, Alzheimer's disease

CHICAGO, Dec. 20, 2022 /PRNewswire/ -- The Alzheimer's Association filed a formal request asking the Centers for Medicare & Medicaid Services (CMS) to provide full and unrestricted coverage for Food and Drug Administration (FDA)-approved Alzheimer's treatments. In its letter, the Association asked CMS to remove the requirements for Coverage with Evidence Development (CED) in its national coverage determination (NCD) for FDA-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease.

Key Points: 
  • As new and better treatments for Alzheimer's disease receive FDA approval, early access to these disease-modifying therapies is crucial.
  • "Each day matters when it comes to slowing the progression of this disease," said Joanne Pike, DrPH, Alzheimer's Association president and incoming chief executive officer.
  • "The current CMS policy to severely limit access to these treatments eliminates people's options, is resulting in continued irreversible disease progression, and contributes to greater health inequities.
  • "For people living with this fatal disease and their families, there is no time to waste," said Dr. Pike.

ELISpot and FluoroSpot Assay Market Report 2022: Increasing Use of Elispot and Fluorospot Assays in Oncology Fuels Sector

Retrieved on: 
Thursday, December 1, 2022
ELISpot, Growth, Hospital, ELISA, Research, Transplant, Biotechnology, USD, Diagnosis, NCD, Vaccine, Assay, Analyser

Market is driven by factors such as increasing use of ELISpot and FluoroSpot assays in oncology, growth in biotechnology and biopharmaceutical industries.

Key Points: 
  • Market is driven by factors such as increasing use of ELISpot and FluoroSpot assays in oncology, growth in biotechnology and biopharmaceutical industries.
  • The Assay kits accounted for the largest market share in the ELISpot and FluoroSpot Assays product' market, during the forecast period
    The ELISpot and FluoroSpot Assay Products market is segmented into Assay kits, Analyzers, and Ancillary Products.
  • Based on type of application, the ELISpot and FluoroSpot Assays market is segmented into Diagnostic and Research Application.
  • The global ELISpot and FluoroSpot Assays market is divided into four regions: North America, Asia-Pacific, Europe, and Rest of the World.

NCD examines alternatives to popular prescription drug cost-effectiveness method that can discriminate

Retrieved on: 
Monday, November 28, 2022
CEA, QALY, Disability, Plasma protein binding, Organization, Prescription, Devaluation, Policy, Patient, Life, National Council on Disability, Value, National Council, Congress, NCD, Health insurance

WASHINGTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Today the National Council on Disability releases a policy brief that examines alternatives to a popular prescription drug cost-effectiveness methodology that has the potential to discriminate against people with disabilities.

Key Points: 
  • WASHINGTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Today the National Council on Disability releases a policy brief that examines alternatives to a popular prescription drug cost-effectiveness methodology that has the potential to discriminate against people with disabilities.
  • Alternatives to QALY-Based Cost-Effectiveness Analysis for Determining the Value of Prescription Drugs and Other Health Interventions supplements NCDs 2019 report, Quality Adjusted Life Years and the Devaluation of Life with a Disability .
  • With this brief, we have explored alternatives to a methodology that often does.
  • NCD is an independent, bipartisan federal agency that advises the President, Congress and other federal agencies on disability policy.

NCD urges HCBS strengthening, calls for ‘Community Living Bias’ in view of COVID-19 death toll

Retrieved on: 
Wednesday, November 16, 2022
COVID-19, Data collection, Housing, Disability, Deinstitutionalisation, Medicaid, Ecosystem, Dangers, Dream House for Medically Fragile Children, Policy, National Council on Disability, Death, National Council, Congress, NCD, Ridesharing company, Pharmaceutical industry

Currently, 820,000 people with disabilities remain on wait lists to transfer out of institutional settings.

Key Points: 
  • Currently, 820,000 people with disabilities remain on wait lists to transfer out of institutional settings.
  • In many instances, social distancing wasnt achievable and the inability to transition out of such a setting became a death trap.
  • Severe shortages of direct care workers and available affordable, accessible housing are just two examples are longstanding fragilities in the HCBS ecosystem, said the Chairman.
  • NCD is an independent, bipartisan federal agency that advises the President, Congress and other federal agencies on disability policy.

ELISpot and FluoroSpot Assay Market Report 2022: Use of FluoroSpot Assays for Multiple-Analyte Detection in Single Well Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, November 25, 2022
Research, Other Health, General Health, Medical Devices, Infectious Diseases, Hospitals, Health Technology, Science, COVID-19, Biotechnology, Medical Supplies, Health, Other Science, ELISpot, Growth, Hospital, ELISA, Research, Transplant, Biotechnology, USD, Diagnosis, NCD, Vaccine, Assay, Analyser

Market is driven by factors such as Increasing use of ELISpot and FluoroSpot assays in oncology, growth in biotechnology and biopharmaceutical industries.

Key Points: 
  • Market is driven by factors such as Increasing use of ELISpot and FluoroSpot assays in oncology, growth in biotechnology and biopharmaceutical industries.
  • The Assay kits accounted for the largest market share in the ELISpot and FluoroSpot Assays product' market, during the forecast period
    The ELISpot and FluoroSpot Assay Products market is segmented into Assay kits, Analyzers, and Ancillary Products.
  • Based on type of application, the ELISpot and FluoroSpot Assays market is segmented into Diagnostic and Research Application.
  • The global ELISpot and FluoroSpot Assays market is divided into four regions: North America, Asia-Pacific, Europe, and Rest of the World.

UAE Genetic Testing Market Report 2022: Increasing Application Of Genetic Testing In Oncology Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 17, 2022
Genetics, Health, Other Health, Genetic, Prevalence, Birth defect, Channel, Genetics, IVI, WHO, Prognosis, NCD, Government, NSG, Cancer, Hospital, USD, Molecular biology, Application, Genetic testing, Mortality, Telecommunications Regulatory Authority (UAE), Organization, DNAS, Degenerative disease, Health, Patient, Sequencing, Incidence, Agriculture, Vaccine

The "UAE Genetic Testing Market Size, Share & Trends Analysis Report by Technology (Next-generation Sequencing, Array Technology), by Application, by Channel, by End-use, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "UAE Genetic Testing Market Size, Share & Trends Analysis Report by Technology (Next-generation Sequencing, Array Technology), by Application, by Channel, by End-use, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The UAE genetic testing market size is expected to reach USD 120.82 million by 2030.
  • According to WHO 2020 report, the UAE has a cancer incidence and mortality of 4,807 and 1,896, respectively.
  • The ancestry & ethnicity application segment held the highest share of the genetic testing market, owing to the significant decrease in the cost of tests.

Tele-Intensive Care Unit Global Market Report 2022: Increase in ICU Admission Rates & High Adoption of Tele-ICUs Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 3, 2022
Other Health, General Health, Telemedicine, Virtual Medicine, Medical Devices, Hospitals, Health Technology, Surgery, Cardiology, Medical Supplies, Practice Management, Health, Diabetes, High-dependency unit, Non-communicable disease, Mortality, Conditional sentence, National Association Medical Staff Services, Intensive care unit, Growth, City, Critical care, Death, Nursing, Population, National Safety Council, Sepsis, LMIC, Degenerative disease, Poisoning, Cardiovascular disease, Prevalence, Partnership, Infection, NCD, Falls, ICU, Chronic obstructive pulmonary disease, Diabetes, Disease, HIC, Length of stay, Patient, Person, Efficiency, Medicine, Hospital, APACHE

The "Tele-Intensive Care Unit (ICU) Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tele-Intensive Care Unit (ICU) Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • In recent years, the number of patients requiring ICU care has increased without a corresponding growth in the availability of intensivists.
  • Critical care is in high demand due to a dearth of intensivists, a smaller number of ICUs, and the expansion of the pandemic.
  • Tele-ICU makes remote critical care and full-time bedside care accessible as the demand for critical care and full-time bedside care grows.